We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $20B
1-Year Est. Return 154.41%
This Fund
S&P 500
This Quarter Est. Return
+0.81%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$22.8B
AUM Growth
+$1.74M
Cap. Flow
+$81.8M
Cap. Flow %
0.36%
Top 10 Hldgs %
82.65%
Holding
132
New
12
Increased
20
Reduced
6
Closed
10

Top Buys

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$137M
2
PACB icon
Pacific Biosciences
PACB
+$66.5M
3
KOD icon
Kodiak Sciences
KOD
+$50.2M
4
BLUE
bluebird bio
BLUE
+$50.2M
5
TVTX icon
Travere Therapeutics
TVTX
+$34M

Top Sells

Rank Stock Value
1
APLS
Apellis Pharmaceuticals
APLS
+$144M
2
ADCT icon
ADC Therapeutics
ADCT
+$34.5M
3
AMRN
Amarin Corp
AMRN
+$22.6M
4
PTGX icon
Protagonist Therapeutics
PTGX
+$20.4M
5
NVTA
Invitae Corporation
NVTA
+$11M

Sector Composition

Rank Sector Weight
1 Healthcare 99.14%
2 Miscellaneous 0.85%
3 Financials 0.01%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SGEN
1
DELISTED
Seagen Inc. Common Stock
SGEN
$8.03B 35.26%
47,288,259
– –
ONC
2
BeOne Medicines Ltd
ONC
$39.2B
$4.24B 18.6%
11,668,897
– –
INCY icon
3
Incyte
INCY
$24.8B
$2.2B 9.67%
32,022,125
+393
+0% +$29.9K
KOD icon
4
Kodiak Sciences
KOD
$2.08B
$1.41B 6.19%
14,681,304
+543,423
+4% +$50.2M
ASND icon
5
Ascendis Pharma A/S
ASND
$17.4B
$724M 3.18%
4,541,604
+1,001,334
+28% +$137M
ACAD icon
6
Acadia Pharmaceuticals
ACAD
$4.74B
$696M 3.06%
41,910,704
– –
BMRN icon
7
BioMarin Pharmaceuticals
BMRN
$12.9B
$589M 2.59%
7,620,494
+31,200
+0.4% +$2.46M
ARGX icon
8
argenx
ARGX
$61.6B
$338M 1.48%
1,119,557
– –
PRLD icon
9
Prelude Therapeutics
PRLD
$366M
$316M 1.39%
10,123,824
– –
NVTA
10
DELISTED
Invitae Corporation
NVTA
$281M 1.23%
9,873,488
-375,087
-4% -$11M
MRTX
11
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$249M 1.1%
1,409,784
– –
ABCL icon
12
AbCellera Biologics
ABCL
$3.62B
$209M 0.92%
10,450,180
– –
IGMS
13
DELISTED
IGM Biosciences
IGMS
$208M 0.91%
3,156,102
– –
BCRX icon
14
BioCryst Pharmaceuticals
BCRX
$2.1B
$183M 0.8%
12,710,818
– –
KYMR icon
15
Kymera Therapeutics
KYMR
$9.53B
$140M 0.62%
2,384,742
+425,531
+22% +$24.7M
PACB icon
16
Pacific Biosciences
PACB
$420M
$139M 0.61%
5,444,963
+2,242,991
+70% +$66.5M
MDGL icon
17
Madrigal Pharmaceuticals
MDGL
$12.3B
$120M 0.53%
1,499,213
– –
LEGN icon
18
Legend Biotech
LEGN
$3.6B
$120M 0.52%
2,364,003
+699,469
+42% +$29.1M
AMRN
19
Amarin Corp
AMRN
$291M
$111M 0.49%
1,092,802
-229,869
-17% -$22.6M
IMCR icon
20
Immunocore
IMCR
$1.68B
$93.4M 0.41%
2,520,730
– –
HRTX icon
21
Heron Therapeutics
HRTX
$59.9M
$86.9M 0.38%
8,131,678
– –
CERS icon
22
Cerus
CERS
$514M
$83.5M 0.37%
13,713,195
– –
GBT
23
DELISTED
Global Blood Therapeutics, Inc.
GBT
$82M 0.36%
3,217,441
– –
ALLK
24
DELISTED
Allakos
ALLK
$74.4M 0.33%
703,050
– –
NRIX icon
25
Nurix Therapeutics
NRIX
$2.6B
$73.5M 0.32%
2,454,082
– –
1
2 3 4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Baker Bros. Advisors's Q3 2021 Portfolio in Review

As of Q3 2021, Baker Bros. Advisors held 132 positions worth $22.8B, up 0.01% from $22.8B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Baker Bros. Advisors's Q3 2021 filing shows 12 new, 20 increased, 6 reduced and 10 closed positions. Its largest new stake was Surrozen: 166,667 shares worth $17.7M. The largest sale was Apellis Pharmaceuticals, an estimated $144M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 99% a quarter earlier, followed by Miscellaneous and Financials.

  • Baker Bros. Advisors's largest Q3 2021 buy was Surrozen: 166,667 shares worth $17.7M.
  • Baker Bros. Advisors added most to Ascendis Pharma A/S in Q3 2021, an estimated $137M increase.
  • Baker Bros. Advisors's biggest Q3 2021 reduction was Amarin Corp, cutting an estimated $22.6M.
  • Baker Bros. Advisors fully exited Apellis Pharmaceuticals in Q3 2021, selling an estimated $144M.
  • Baker Bros. Advisors's ten largest holdings make up 83% of its $22.8B portfolio in Q3 2021.
  • Baker Bros. Advisors opened 12 new positions and closed 10 in Q3 2021.
  • Baker Bros. Advisors's portfolio value rose 0.01% quarter-over-quarter to $22.8B.

Based on Baker Bros. Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.